Figure 3
From: Pretreatment PSA levels affects the completion rate of Ra-223 treatment
Changes in biomarkers during Ra-223 treatment. (a) PSA, (b) ALP and (c) BAP. p-values in change ratios from baseline between the complete and incomplete groups after the third administration. Mean PSA levels tended to increase throughout the entire Ra-223 treatment period in both the complete and the incomplete groups, however significant difference was seen between the two groups (p = 0.04). Mean ALP and BAP levels decreased after the third administration in the complete group, compared with baseline (mean change ratios 0.77 and 0.68, respectively), while levels in the incomplete group increased (mean change ratios 1.38 and 1.16, respectively). Significant difference was seen in ALP levels (p = 0.03), while was not seen in BAP levels (p = 0.08) between the two groups. PSA; prostate specific antigen, ALP; alkaline phosphatase, BAP; bone-specific alkaline phosphatase, N.S.; not significant.
